phonecontact
cards

Category: General - Part 5

Oasmia Leveraging Platform, Advancing Veterinary Medicines

Oasmia Pharmaceuticals (NASDAQ: OASM) is firing on all cylinders. Earlier this week, the company announced positive overall survival (OS) data from its Phase 3 clinical study with Paclical/Apealea® for the treatment of ovarian cancer. After completing six treatment cycles, patients on Paclical/Apealea® plus carboplatin had a median overall survival of 25.7 months compared to 24.8 months…

CoLucid – Facts About Migraine

This article is a quick introduction to CoLucid Pharmaceuticals (NASDAQ: CLCD) and the company’s  first-in-class 5-HT1F receptor agonist, lasmiditan (COL-144), for the acute treatment of migraine. An oral formulation of lasmiditan is currently in Phase 3 development and an intravenous formulation for use in the emergency room setting is in Phase 2 clinical trials. The…

BriaCell Identifies Biomarkers Consistent With Uber-Response to BriaVax

Company Obtains Funding For Initiation Of Phase I/II Clinical Trial Last week, at the American Association for Cancer Research (AACR) annual meeting, scientists from BriaCell Therapeutics Corp. (TSXV: BCT) (OTC: BCTXF) presented research on the molecular profile of BriaVax™, the company’s proprietary whole tumor cell vaccine. The findings (AACR #2369) are suggestive of the BriaVax™ mechanism…

BriaCell To Initiate Phase 2 Trial With Targeted Cancer Immunotherapy

In the past week, BriaCell Therapeutics Corp (BCT.V) (BCTXF) provided an update for investors on the status of BriaVax™, the company’s proprietary whole tumor cell vaccine for the treatment of late-stage cancer. I continue to be intrigued by BriaCell and what the company is doing in immuno-oncology. The stock is largely unheard-of by retail investors…

Oasmia Looks To Duplicate Success With A Validated Model

Last month I wrote a detailed article introducing investors to Oasmia Pharmaceuticals (NASDAQ:OASM), a Swedish-based biopharmaceutical company developing next-generation novel formulations of well-established chemotherapeutic agents through its proprietary nanotechnology platform. Shares of Oasmia are up 50% since that article, and I think the upward momentum in the stock will continue based on some recent positive…

How BioSig Technologies Is Positioned To Change the Electrophysiology Market

BioSig Technologies, Inc. (BSGM) is a Minnesota-based medical device company developing a proprietary technology platform designed to improve the rapidly growing multi-billion dollar electrophysiology (EP) marketplace. The company’s leading product is Pure EP™, a surface electrocardiogram (EKG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists during catheter ablation procedures to treat cardiac…

SRNT Abstracts on SPECTRUM® Cigarettes Show Potential Market Opportunity For 22nd Century Group

The Society for Research on Nicotine & Tobacco (SRNT) held its Annual Meeting in Chicago, IL on March 2-5, 2016. At that meeting, 15 independently conducted scientific studies with SPECTRUM® Cigarettes were presented in oral presentation or poster form. SPECTRUM® is a brand of “research cigarette” commissioned by the National Institute on Drug Abuse (NIDA), along with…

Oasmia Pharmaceuticals – Advancing Nanotechnology Based Chemotherapies

Oasmia Pharmaceuticals AB (NASDAQ: OASM) is a Swedish-based biopharmaceutical company developing next-generation novel formulations of well-established chemotherapeutic agents through its proprietary nanotechnology platform. Compared to existing cytostatic agents, Oasmia’s improved formulations offer reduced side-effects, potentially leading to expanded therapeutic use, as well as reduced infusion time, better pharmacologic profile, and superior bioavailability. The lead product…

RedHill Biopharma Packed With Catalysts In 2016

On February 25, 2016, RedHill Biopharma Ltd. (RDHL) reported financial results for the fourth quarter and full year ending December 31, 2015. The company also hosted a conference call with investors to highlight the operational results from 2015 and provide an update on the late-stage pipeline. There are a tremendous number of catalysts for RedHill…

Fourth Quarter Results Show What’s To Come For 22nd Century Group

On February 18, 2016, 22nd Century Group, Inc. (NYSE MKT: XXII) filed its Form 10K annual report for the year ending December 31, 2015. Early this morning the company held a conference call to provide an update for shareholders. Given that the company’s two key cigarette brands, MAGIC® and RED SUN®, are still in the early stages…